| Name | Title | Contact Details |
|---|
Hexagon Bio is a data-driven biotech developing targeted small molecule therapeutics.
Learn why 2,000+ healthcare organizations and employers depend on our experts to improve patient outcomes with advanced diagnostics.
C4 Therapeutics is pioneering a new class of drugs. C4`s technology platform produces small molecule drugs that harness machinery already present in cells to selectively target disease-relevant proteins for degradation. Our approach has the potential to address a broad range of diseases including cancer, infectious disease, and autoimmune disorders.
We are harnessing the power of the immune system to target some of the most challenging solid tumor malignancies.
There are approximately 7,000 rare disorders worldwide. Each day more are being discovered. 95% of rare diseases have not one single FDA approved treatment. Glycomine develops therapeutics for diseases which have no treatment options.